Freestone Capital Holdings LLC Acquires 7,242 Shares of DexCom, Inc. $DXCM

Freestone Capital Holdings LLC lifted its stake in DexCom, Inc. (NASDAQ:DXCM) by 32.1% during the second quarter, HoldingsChannel.com reports. The firm owned 29,823 shares of the medical device company’s stock after purchasing an additional 7,242 shares during the quarter. Freestone Capital Holdings LLC’s holdings in DexCom were worth $2,603,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. SWS Partners purchased a new stake in shares of DexCom in the second quarter worth $1,661,000. Baader Bank Aktiengesellschaft bought a new position in DexCom in the 2nd quarter worth $393,000. Jennison Associates LLC increased its stake in DexCom by 9.4% in the 2nd quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock worth $1,005,367,000 after buying an additional 994,300 shares in the last quarter. Mn Services Vermogensbeheer B.V. raised its holdings in DexCom by 4.9% during the second quarter. Mn Services Vermogensbeheer B.V. now owns 146,600 shares of the medical device company’s stock valued at $12,797,000 after acquiring an additional 6,800 shares during the period. Finally, Assenagon Asset Management S.A. lifted its position in shares of DexCom by 85.7% in the second quarter. Assenagon Asset Management S.A. now owns 1,208,255 shares of the medical device company’s stock valued at $105,469,000 after acquiring an additional 557,576 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on DXCM shares. Raymond James Financial upped their price target on DexCom from $99.00 to $102.00 and gave the stock a “strong-buy” rating in a research note on Thursday, July 31st. UBS Group dropped their target price on shares of DexCom from $106.00 to $95.00 and set a “buy” rating for the company in a research report on Monday. Cowen reaffirmed a “buy” rating on shares of DexCom in a research note on Friday, October 24th. JPMorgan Chase & Co. decreased their price target on shares of DexCom from $90.00 to $75.00 and set a “neutral” rating on the stock in a research note on Friday. Finally, The Goldman Sachs Group dropped their price objective on shares of DexCom from $104.00 to $89.00 and set a “buy” rating for the company in a report on Wednesday, October 1st. Three research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $89.33.

Insider Buying and Selling at DexCom

In other news, EVP Michael Jon Brown sold 500 shares of the company’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $80.29, for a total value of $40,145.00. Following the completion of the sale, the executive vice president owned 94,102 shares of the company’s stock, valued at approximately $7,555,449.58. This represents a 0.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Sadie Stern sold 1,466 shares of the stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $80.00, for a total value of $117,280.00. Following the sale, the executive vice president directly owned 105,223 shares in the company, valued at $8,417,840. This trade represents a 1.37% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 5,383 shares of company stock valued at $434,274 in the last 90 days. Insiders own 0.32% of the company’s stock.

DexCom Stock Up 3.8%

Shares of NASDAQ DXCM opened at $60.43 on Tuesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The company has a market cap of $23.70 billion, a P/E ratio of 41.97, a PEG ratio of 1.43 and a beta of 1.47. DexCom, Inc. has a 1 year low of $56.44 and a 1 year high of $93.25. The firm has a 50-day simple moving average of $70.63 and a two-hundred day simple moving average of $77.97.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.04. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. During the same period last year, the company earned $0.45 earnings per share. The business’s revenue for the quarter was up 21.6% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. Research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.